News & Articles

In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years

New partnership broadens access to oncology treatments across Latin America, Asia, Africa and the Western Pacific

These findings are crucial as rapidly spreading variants of SARS-CoV-2 have been reported in various countries

In a 17-4 vote, the FDA vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the U.S.

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in pregnant women

The COVID-19 vaccine trial is part of a global development program that will uncover the safety and immunogenicity of four mRNA vaccine candidates.

Following regulatory approval, the first clinical trial of the coronavirus vaccine candidates is said to commence in late April

Chairman and CEO Albert Bourla calls on biopharma industry to collaborate on combating the global pandemic

Welcoming more than 250 delegates and over 70 prestigious moderators and panelists, Pharma Integrates takes place on 15-16 November at the Grange City Hotel, London